1. Home
  2. TRX vs AVTX Comparison

TRX vs AVTX Comparison

Compare TRX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TRX Gold Corporation

TRX

TRX Gold Corporation

HOLD

Current Price

$1.30

Market Cap

383.1M

Sector

N/A

ML Signal

HOLD

Logo Avalo Therapeutics Inc.

AVTX

Avalo Therapeutics Inc.

HOLD

Current Price

$16.55

Market Cap

982.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRX
AVTX
Founded
1990
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.1M
982.5M
IPO Year
2002
2015

Fundamental Metrics

Financial Performance
Metric
TRX
AVTX
Price
$1.30
$16.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$1.70
$40.57
AVG Volume (30 Days)
2.9M
862.7K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
72.07
EPS
N/A
N/A
Revenue
N/A
$27,813,137.00
Revenue This Year
$84.84
N/A
Revenue Next Year
$96.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2312.27
52 Week Low
$0.54
$10.70
52 Week High
$2.80
$24.27

Technical Indicators

Market Signals
Indicator
TRX
AVTX
Relative Strength Index (RSI) 60.95 37.15
Support Level $1.23 $12.98
Resistance Level $1.31 $16.80
Average True Range (ATR) 0.07 1.00
MACD -0.00 -0.29
Stochastic Oscillator 80.43 21.18

Price Performance

Historical Comparison
TRX
AVTX

About TRX TRX Gold Corporation

TRX Gold Corp is a high-margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open-pit operation and approximately 2,000 tonnes per day process plant with upside potential demonstrated. The group is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold's actions are led by the highest environmental, social, and corporate governance (ESG) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Share on Social Networks: